In August, we added 117 citations in DIDB, including 63 in vitro (with 23 articles published in August 2023) and 54 in vivo articles (with 30 articles published in August 2023).
3 recently approved NDAs/BLAs were also added: glofitamab (COLUMVI), nirsevimab (BEYFORTUS), quizartinib (VANFLYTA)
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
In July, we added 110 citations in DIDB, including 55 in vitro (with 21 articles published in July 2023) and 55 in vivo articles (with 33 articles published in July 2023).
4 recently approved NDAs/BLAs were also added: flotufolastat F-18 gallium (POSLUMA), ritlecitinib (LITFULO), rozanolixizumab (RYSTIGGO), sulbactam and durlobactam (XACDURO)
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated in July 2023, and is available in the DIDB Resource Center.
In this update, 25 compounds were identified as substates, inhibitors, and inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3). Among them, 3 compounds were sensitive substrates and could lead to strong drug interactions mediated by CYP1A2, CYP2D6, and CYP3A.
In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g. dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.
As always, feel free to contact us if you have any questions or comments.
In June, we added 77 citations in DIDB, including 22 in vitro (with 15 articles published in June 2023) and 55 in vivo articles (with 45 articles published in June 2023).
3 recently approved NDAs/BLAs were also added: leniolisib (JOENJA), pegunigalsidase alfa (ELFABRIO), fezolinetant (VEOZAH).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
“We are thrilled to share an important development related to Drug Interaction Solutions (DIS) and the DIDB® – The Drug Interaction Database, which you and your teams have relied on over the years. As of June 21, 2023, DIS and DIDB® have been acquired by Certara – a global leader in biosimulation and technology-enabled services that accelerate drug development.
This move represents a significant milestone in the growth and development of DIDB® and further strengthens its position as an internationally recognized authoritative, unbiased, and transparent drug development tool. As a part of Certara’s data sciences portfolio, we know we have found the right home for DIDB® to continue towards becoming a standard in supporting drug development, healthcare applications, and complex clinical decision algorithms.”
UW CoMotion
In May, we added 107 citations in DIDB, including 45 in vitro (with 14 articles published in May 2023) and 62 in vivo articles (with 39 articles published in May 2023).
2 recently approved NDAs/BLAs were also added: retifanlimab (DAYBUE), tofersen (QALSODY).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
In April, we added 111 citations in DIDB, including 40 in vitro (with 11 articles published in April 2023) and 71 in vivo articles (with 43 articles published in April 2023).
Four recently approved NDAs were also added: elacestrant (ORSERDU), omaveloxolone (SKYCLARYS), trofinetide (DAYBUE), zavegepant (ZAVZPRET).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
In March, we added 105 citations in DIDB, including 51 in vitro (with 16 articles published in March 2023) and 54 in vivo articles (with 38 articles published in March 2023).
Three recently approved NDAs and BLAs were also added: daprodustat (JESDUVROQ), pirtobrutinib (JAYPIRCA), velmanase alfa (LAMZEDE).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated in April 2023, and is available in the DIDB Resource Center.
In this update, 38 compounds were identified as substates, inhibitors, and inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3). Among them, 6 compounds (16%) could lead to strong drug interactions mediated by CYP3A and CYP2D6.
In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g. dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.
As always, feel free to contact us if you have any questions or comments.
In February, we added 94 citations in DIDB, including 38 in vitro (with 16 articles published in February 2023) and 56 in vivo articles (with 38 articles published in February 2023).
Seven recently approved NDAs and BLAs were also added: anacaulase (NEXOBRID), bexagliflozin (BRENZVVY), lecanemab (LEQEMBI), lenacapavir (SUNLENCA), mosunetuzumab (LUNSUMIO), ublituximab (BRIUMVI), xenon Xe-129 hyperpolarized (XENOVIEW).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.